M-NM-23 agonist administration before reperfusion reduces infarct size and improves long term cardiac function in small and large animal models of myocardial infarction

ABSTRACT: RNA sequencing and subsequent bioinformatics analyses were performed at early reoxygenation stages in HL-1 cardiomyocytes treated or not with BRL37344 Methods: HL-1 cardiomyocytes were subjected to Hypoxia/Reoxygenation (6h/1h) with/without a M-NM-23AR agonist (BRL37344 5M-BM-5mol/L). mRNA profiles were generated by deep sequencing, in triplicate, using Illumina GAIIx.The sequence reads that passed quality filters were quantified using BWA aligned reads using RSEM. qRTM-bM-^@M-^SPCR validation was performed using SYBR Green assay. Results: After 6h of hypoxia followed by 1h reoxygenation, 866 genes were differentially expressed upon M-NM-23AR stimulation by BRL37344. Among these, 177 were at least 2-fold up or downregulated. Conclusions: Our results show that Hsp70 plays a key role in the cardioprotection afforded by M-NM-23AR agonism in cardiomyocytes during the early window of H/R. mRNA profiles from cardiomyocyte subjected to H/R (6h/1h) with/without a M-NM-23AR agonist were generated by deep sequencing, in triplicate, using Illumina GAIIx.

ORGANISM(S): Mus musculus

SUBMITTER: David Sanz-Rosa 

PROVIDER: E-GEOD-42999 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress